Ignite Creation Date:
2024-05-06 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06154343
Status:
RECRUITING
Last Update Posted:
2023-12-04
First Post:
2023-11-23
Brief Title:
A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
Sponsor:
GeneQuantum Healthcare Suzhou Co Ltd
Organization:
GeneQuantum Healthcare Suzhou Co Ltd
Study Overview
Official Title:
A Phase 1 First-In-Human Multicenter Open-LabelDose-Escalation and Extension Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label phase I study to evaluate the safety tolerability pharmacokinetics and immunogenicity of GQ1005 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None